[AEZS] AEterna Zentaris Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 4.1 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart AEZS

Refresh chart

Strongest Trends Summary For AEZS

AEZS is in the medium-term down -45% below S&P in 6 months. In the long-term down -100% below S&P in 13 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Aeterna Zentaris Inc., a specialty biopharmaceutical company, is focused on developing and commercializing novel treatments in oncology and endocrinology. The company?s product pipeline includes MACRILEN, for which a New Drug Application is under review by the FDA as an oral product used for evaluating adult growth hormone deficiency. MACRILEN is also investigated in a Phase 2A clinical trial to treat cancer-induced cachexia. Its product pipeline also comprises zoptarelin doxorubicin, which is in the ZoptEC (zoptarelin doxorubicin in Endometrial Cancer) Phase 3 trial in women with advanced, recurrent, or metastatic endometrial cancer. In addition, the company?s preclinical product candidates in oncology include AEZS-120, a live recombinant oral tumor vaccine candidate; PI3K/Erk inhibitors, including AEZS-129 and AEZS-136; and disorazol Z product candidates, such as AEZS-137 and AEZS-138. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Quebec City, Canada.

Fundamental Ratios
Shares Outstanding EPS-2.34 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-0.41
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities28.74 M Cash From Investing Activities490 K Cash From Operating Activities-10.19 M Gross Profit
Net Profit-9.74 M Operating Profit-9.54 M Total Assets65.27 M Total Current Assets55.55 M
Total Current Liabilities6.32 M Total Debt Total Liabilities44.89 M Total Revenue70 K
Technical Data
High 52 week5.43 Low 52 week1.3 Last close2.39 Last change-4.78%
RSI44.53 Average true range0.16 Beta0.71 Volume222.87 K
Simple moving average 20 days-2.94% Simple moving average 50 days-8.69% Simple moving average 200 days-27.38%
Performance Data
Performance Week1.7% Performance Month-8.78% Performance Quart-25.08% Performance Half-42.41%
Performance Year20.26% Performance Year-to-date-18.71% Volatility daily5.23% Volatility weekly11.69%
Volatility monthly23.96% Volatility yearly82.99% Relative Volume301.76% Average Volume110.89 K
New High New Low


2019-08-20 23:16:00 | Aeterna Zentaris Announces Director Change

2019-08-13 17:45:09 | Aeterna Zentaris AEZS Beats Q2 Earnings Estimates

2019-08-13 16:15:00 | Aeterna Zentaris Reports Second Quarter 2019 Financial and Operating Results

2019-08-01 10:33:02 | Will Aeterna Zentaris AEZS Report Negative Q2 Earnings? What You Should Know

2019-07-01 10:30:02 | Options Traders Expect Huge Moves in Aeterna Zentaris AEZS Stock

2019-06-06 14:06:40 | Aeterna Zentaris Provides Corporate Update

2019-05-08 18:04:22 | Aeterna Zentaris Announces Results of Annual and Special Shareholders’ Meeting

2019-05-07 19:25:11 | Aeterna Zentaris AEZS Reports Q1 Loss, Misses Revenue Estimates

2019-05-07 18:22:18 | Aeterna Zentaris: 1Q Earnings Snapshot

2019-05-07 17:12:12 | Aeterna Zentaris Reports First Quarter 2019 Financial and Operating Results

2019-05-02 10:02:02 | What's in the Cards for AEterna AEZS This Earnings Season?

2019-04-29 10:31:02 | Analysts Estimate Aeterna Zentaris AEZS to Report a Decline in Earnings: What to Look Out for

2019-03-26 19:50:43 | Aeterna Zentaris: 4Q Earnings Snapshot

2019-03-26 17:22:03 | Aeterna Zentaris Reports Fourth Quarter and Full-Year 2018 Financial and Operating Results

2019-03-19 08:00:00 | Aeterna Zentaris to Announce Fourth Quarter and Year End 2018 Financial and Operating Results on March 26, 2019

2019-03-18 11:18:03 | Aeterna Zentaris AEZS Moves to Buy: Rationale Behind the Upgrade

2019-03-13 07:27:36 | The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie

2019-03-12 16:32:37 | Aeterna Zentaris Announces Strategic Review and Engagement of Financial Advisor

2019-03-04 08:58:01 | What's in the Cards for Aeterna AEZS This Earnings Season?

2019-02-27 09:57:02 | The Zacks Analyst Blog Highlights: Celgene, Charles River Laboratories International, Catalent and Aeterna Zentaris

2019-02-26 08:55:01 | 4 Drug Stocks to Buy Despite Price Hearing Woes

2019-02-14 10:45:03 | The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna

2019-02-13 08:36:01 | 5 Tiny Biotech Stocks With Superb Growth Potential

2019-01-29 09:30:02 | Is AEterna Zentaris AEZS Outperforming Other Medical Stocks This Year?

2019-01-29 08:48:01 | Implied Volatility Surging for Aeterna Zentaris AEZS Stock Options

2019-01-16 09:03:00 | Aeterna Zentaris Receives European Marketing Clearance for Macimorelin

2019-01-09 09:50:02 | Amgen's Osteoporosis Candidate Evenity Gets Approval in Japan

2019-01-07 09:30:02 | Is AEterna Zentaris AEZS Outperforming Other Medical Stocks This Year?

2018-12-24 17:50:10 | Aeterna Zentaris AEZS Stock Moves -1.16%: What You Should Know

2018-12-21 17:04:32 | Aeterna Zentaris Settles Dispute with David Dodd and Philip Theodore

2018-12-20 09:30:02 | Is AEterna Zentaris AEZS Stock Outpacing Its Medical Peers This Year?

2018-12-17 17:50:10 | Aeterna Zentaris AEZS Gains As Market Dips: What You Should Know

2018-12-07 17:45:10 | Aeterna Zentaris AEZS Stock Moves -0.54%: What You Should Know

2018-12-04 12:51:05 | Is AEterna Zentaris AEZS Stock Outpacing Its Medical Peers This Year?

2018-11-30 05:41:10 | Can The Uptrend Continue for Aeterna Zentaris AEZS?

2018-11-19 09:00:00 | 4 Healthcare Stocks Taking a New Approach to Growth Trends

2018-11-19 08:00:00 | Aeterna Zentaris AEZS Receives Positive CHMP Opinion of Macimorelin for Diagnosis of Adult Growth Hormone Deficiency

2018-11-16 10:50:00 | 4 Healthcare Stocks Turning Toward Tech For New Growth

2018-11-16 07:40:00 | Consolidated Research: 2018 Summary Expectations for Western Gas Partners, LP, HCA Healthcare, DHI Group, AEterna Zentaris, Tsakos Energy Navigation, and Acme United — Fundamental Analysis, Key Performance Indications

2018-11-06 19:54:11 | Aeterna Zentaris: 3Q Earnings Snapshot

2018-11-06 18:14:02 | Aeterna Zentaris Reports Third Quarter 2018 Financial and Operating Results

2018-11-06 08:00:00 | Aeterna Zentaris Settles Dispute with Cogas Consulting, LLC

2018-11-01 08:20:00 | Aeterna Zentaris Soars on MacrilenTM Out Licensing Deal, Analysts Review and Target

2018-11-01 08:00:00 | Aeterna Zentaris Announces Novo Nordisk to acquire rights to Macrilen™ in United States and Canada

2018-11-01 07:50:00 | Today’s Research Reports on Stocks to Watch: Aeterna Zentaris and AbbVie

2018-10-31 16:05:00 | Aeterna Zentaris to Announce Third Quarter 2018 Financial and Operating Results on November 6, 2018

2018-10-31 12:00:00 | 3 Healthcare Stocks Leading New Industry Trends

2018-09-25 08:00:00 | Aeterna Zentaris Appoints Leslie Auld as Chief Financial Officer

2018-08-10 07:27:36 | What is Behind Aeterna Zentaris Inc’s TSE:AEZS Superior ROE?

2018-08-10 06:30:00 | Aeterna Zentaris Inc. to Host Earnings Call